Zimmer Biomet Holdings Inc vs Zeta Global Holdings Corp — how do they compare? Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B), while Zeta Global Holdings Corp trades at $30.45 (market cap $7.73B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.3× Zeta Global Holdings Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| ZBH | ZETA | |
|---|---|---|
Market Cap | $17.97B | $7.73B |
Sector | Health | Technology |
52-Week High | $104.26 | $32.68 |
52-Week Low | $79.58 | $14.55 |
Enterprise Value | $25.04B | $7.62B |
Dividend Yield | 1.02% | — |
Signals from Pluang's Aura AI — not financial advice
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
ZETA trades at $30.79, down 1.79% today but maintains strong institutional support with 75% analyst buy ratings. The stock shows bullish technical signals with consecutive earnings beats and 44% revenue growth in Q2 2026. Recent news highlights AI platform expansion and partnership opportunities driving investor optimism despite negative net margins.
Outlook remains positive with revenue growth accelerating to $1.6B projected for 2026 and consensus price target of $31.19 offering 1.3% upside. Key risks include rich valuation (P/S 4.59x) and execution challenges in competitive marketing tech space, though AI adoption and institutional inflows support bullish thesis.
Trailing returns across standard periods
Latest headlines on both assets
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →